TrialBlood2015

Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.

Samantha M Jaglowski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.